Drugs / Typhoid Vi Conjugate Vaccine I.P.
Typhoid Vi Conjugate Vaccine I.P.
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06757283 | Apr 2025 → Mar 2026 overdue | typhoid fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typhoid Vi Conjugate Vaccine I.P. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06757283 ↗ |
| Known as | Vi-TCV | “This will be a phase III effectiveness study of the typhoid conjugate vaccine (Vi-TCV) (ZyVac® TCV).” NCT06757283 ↗ |
| Known as | ZyVac TCV | “Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV, Zydus...” NCT06757283 ↗ |
| Modality | Vaccine | “This is a prospective closed cohort, open-label, phase III effectiveness study using a test-negative design of a typhoid conjugate vaccine, ZyVac® TCV” NCT06757283 ↗ |
| Route | Intramuscular | “It will be administered as an intramuscular injection preferably in the anterolateral aspect of the middle thigh for younger children, or the upper arm for older children with...” NCT06757283 ↗ |